



16:00 Wrap up / Highlights						
4007	Lower GI	Conroy	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.	https://meetinglibrary.asco.org/record/185485/video	The RAPIDO and Prodigie 23 regimen becomes an option in high-risk (e.g. T4, N+) an option	
4006	Lower GI	Hospers	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.	https://meetinglibrary.asco.org/record/185464/abstract	The RAPIDO and Prodigie 23 regimen becomes an option in high-risk (e.g. T4, N+) an option	
4001	Lower GI	Kopetz	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).	https://meetinglibrary.asco.org/record/185472/video	In second line BRAFmut CRC Encorafenib+Cetuximab is the new standard	
LBA 4	Lower GI	André	Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study	https://meetinglibrary.asco.org/record/186928/video	Front line MSI testing in CRC Stage IV is compulsory, pembrolizumab is a good front-line therapy option especially if no response is needed	
501	Breast/Gyn	Van der Voort	Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.	https://meetinglibrary.asco.org/record/184908/video	Regarding efficacy the systemic therapy of HER2-pos disease can be deescalated with abandoning anthracyclines in the neoadjuvant setting.	
LBA2	Breast/Gyn	Khan	A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).	https://meetinglibrary.asco.org/record/186884/video	Local therapy for de novo metastatic disease in BC has no impact on overall survival, PFS and Quality of Life	
1005	Breast/Gyn	Lin	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).	https://meetinglibrary.asco.org/record/185141/video	Tucatinib is the first TKI showing a prolongation of OS in pts with brain metastases and HER2-positive disease	
6000	Breast/Gyn	Du Bois	Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.	https://meetinglibrary.asco.org/record/185438/video	Secondary cytoreductive surgery can prolong OS in a highly selected patient population and has to be individually considered in 1st relapse	
5001	Prostate	Shore	HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer	https://meetinglibrary.asco.org/record/191602/video	Daily oral LHRH Antagonist is challenging the current standard of three monthly subcutaneous LHRH Agonist like Goserelin or Leuproreline. More convenient treatment and possible less cardiovascular toxicity.	
LBA 1	Bladder	Powles	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.	https://meetinglibrary.asco.org/record/186872/video	Avelumab maintenance for one year after first-line cis- or carbo plus gemcitabine improves overall survival in metastatic urothelial cancer. This is the first study in first-line metastatic urothelial cancer that can show an overall survival benefit in addition to cis- or carbo gemcitabine alone.	
9001	SCLC	Rudin	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).	https://meetinglibrary.asco.org/record/184545/video	Pembro+EP significantly improved PFS and prolonged OS compared with placebo+ EP as first-line therapy for pts with ES-SCLC. No unexpected toxicities were seen with pembro + EP. These data support the benefit of pembro-containing regimens for ES-SCLC	
9503	NSCLC	Rodriguez-Abreu	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).	https://meetinglibrary.asco.org/record/184799/video	Phase II trial: Treatment with TA compared to PA showed clinically meaningful improvement in ORR and PFS in ITT. The safety profile of TA was similar to PA.	
LBA5	NSCLC	Roy S. Herbst	Osimertinib as adjuvant therapy in patients (pts) with stage IB-III AEGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.	https://meetinglibrary.asco.org/record/184808/video	Phase III trial: Adjuvant osimertinib showed an improvement in DFS in pts with stage IB/II/III A EGFRm NSCLC after complete tumor resection and adjuvant chemotherapy	

Organizer



Founding Sponsor



Roche Pharma (Schweiz) AG
4052 Basel

Co-Sponsors

